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ABSTRACT: Bromodomain containing proteins PB1, SMARCA4, and SMARCA2 are important components of SWI/SNF chro-
matin remodeling complexes. We identified bromodomain inhibitors targeting these proteins, which display unusual binding modes 
involving water displacement from the KAc binding site. The best compound binds the fifth bromodomain of PB1 with a KD of 124 
nM, SMARCA2B and SMARCA4 with KDs of 262 and 417 nM respectively, and displays excellent selectivity over bromodomains 
other than PB1, SMARCA2, and SMARCA4. 
INTRODUCTION  
The structure of chromatin, the complex of proteins and DNA 
through which DNA is packaged, is regulated by the post-
translational modification of histone tails and the action of 
chromatin remodeling complexes such as the Switch/Sucrose 
Non-Fermenting (SWI/SNF) complex. The multi-subunit 
SWI/SNF complex is based on the mutually exclusive hel-
icase/ATPase proteins SMARCA2 and SMARCA4, with addi-
tional core subunits and regulatory or specificity proteins. 
Many components contain domains that recognize histone 
post-translational modifications, enabling cross-talk between 
the two mechanisms of regulation.  
The SWI/SNF complex is subject to considerable research 
interest, since components are mutated in many cancers1–3 and 
are implicated in developmental disorders.4 In some tumor 
types, mutations within the SWI/SNF complex lead to context-
specific vulnerabilities, such as dependence on SMARCA2/4 
in SMARCB1 (Snf5) mutant rhabdoid tumors5 or the essential 
presence of SMARCA2 in SMARCA4-mutant lung cancer.6,7 
The biological roles of the complexes has led to interest in 
generating chemical probes that target different domains with-
in the multi-subunit complex, to assist the elucidation of their 
function and therapeutic relevance.8 Bromodomain containing 
proteins (BCPs) are prevalent in SWI/SNF complexes and are 
present in SMARCA2/4 helicases, BRD7/9, and PB1. 
SMARCA2/4 and BRD7/9 contain one bromodomain each 
whilst PB1 has six distinct bromodomains. In yeast SWI/SNF 
bromodomains are implicated in enhancing chromatin remod-
eling efficiency, loci targeting, and protein-protein interac-
tions.9,10 In eukaryotes the SMARCA4 bromodomain is re-
ported to act in the DNA damage response.11,12 Mutations in 
PB1’s bromodomains have been found in clear cell renal car-
cinoma and linked to genome instability and aneuploidy.13,14 
Bromodomains are protein modules of ~ 110 amino acids that 
recognize acetylated lysine (KAc) and share a common struc-
ture of four alpha helices linked by flexible loop regions and 
have been popular targets for chemical probe development.15,16 
61 bromodomains are expressed in the human proteome, 
across 42 BCPs, which can be grouped into sub-families based 
on amino acid sequence and structural alignment.17 Chemical 
probes have now been developed for multiple sub-families and 
have helped identify new biology.18,19 In particular, com-
pounds (+)JQ1 and IBET-151 have demonstrated the thera-
peutic potential of bromodomain and extra-terminal (BET) 
proteins in cancer, inflammation and heart failure.20–22  
The chemical probes I-BRD923 and LP99,24 targeting BRD9 
and BRD7/BRD9 respectively, have been developed to study 
some bromodomains in the SWI/SNF complex. Recently a 
chemical probe, PFI-3, targeting the bromodomains in 
SMARCA2 and SMARCA4, as well as the fifth bromodomain 
of PB1 (PB1(5)), has been developed based on a salicyclic 
acid fragment hit, and been used to demonstrate a role for 
SMARCA4 in embryonic stem cell maintenance.25 These re-
sults demonstrate that SWI/SNF BCPs are druggable, despite 
 being predicted to be more challenging to target due to a fea-
tureless binding pocket lacking a clearly defined hydrophobic 
groove and ZA binding channel as in BRD4(1) (supporting 
information).17,26 A short ZA loop and a wider entrance than 
BET bromodomains have been identified as factors that may 
alter ligand binding mode in the structurally related bromo-
domains PB1(5) and SMARCA2/4, whilst PB1(2-4) are de-
fined by an aromatic residue in the pocket that is proposed to 
act as a ‘lid’.26 Given the varied structural nature of the six 
bromodomains in PB1, one single probe is unlikely to be able 
to target all simultaneously. Several compounds with different 
chemotypes may be required. 
In the course of library screening, compound 1 and other relat-
ed analogues were found to be weak PB1(5) inhibitors but 
with poor aqueous solubility. In this work we describe the 
optimization of 1, leading to a family of compounds with in-
creased potency, improved physicochemical properties, and 
varied selectivity within the SWI/SNF bromodomains, includ-
ing the potential to target PB1 selectively over SMARCA4 
and SMARCA2 bromodomains. 
 
Figure 1: Initial hit from screening of a commercial library. 
RESULTS AND DISCUSSION 
The library of commercial analogues of 1 showed varied re-
sponse by differential scanning fluorimetry (DSF) against 
PB1(5). DSF has been demonstrated to be an operationally 
simple assay, suitable for rapid assessment of potency and 
selectivity for bromodomains.19,24,27 Limited SAR from the 
library indicated sensitivity to the size of the aromatic side 
chain and that the 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-
one core bound within the KAc binding site (supporting in-
formation). We proposed that planarity of the compounds with 
conjugated aromatic ring substituents contributed to the poor 
solubility of the series and that analogues with greater sp3 
character in their substituents, or the potential for ionization, 
would have improved aqueous solubility.28  
Compounds were synthesized by the routes shown in Scheme 
1. Amidation of 2-aminobenzamide 2 with 4-chlorobutanoyl 
chloride29 gave amide 3, which could be cyclized to the 2,3-
dihydropyrrolo[1,2-a]quinazolin-5(1H)-one core 4 using po-
tassium tert-butoxide. The isomer was confirmed on the basis 
of NOE correlations and subsequent crystallography. The 
weak nucleophilicity of the core was then exploited by react-
ing compound 4 with substituted N,N-dialkylformamides us-
ing Vilsmeier-Haack conditions, giving analogues incorporat-
ing nitrogen-based aliphatic side chains solely as the E regioi-
somer. This chemistry was unsuitable for piperazine-based 
formamides. For these side chains, analogues 12-15 were syn-
thesized as single regioisomers by displacement of the dime-
thylamino group in compound 5 using cyclic secondary 
amines and DMAP catalysis. Due to the potential for hydroly-
sis of the enamine-like moiety, the aqueous stability of com-
pound 5 was assessed by 1H-NMR in a D2O time course ex-
periment and was stable for >24 hours. All analogues appeared 
to have increased aqueous solubility compared to compound 1.  
Their binding to PB1(5) was assessed by the operationally 
simple DSF assay (Table 1). Although the simple scaffold 4 
itself showed no interaction, aliphatic analogues 5-15 general-
ly showed improved binding to PB1(5). The shape of the side 
chain was a key factor in determining activity; inclusion of 
propyl side chains in 7 led to moderate activity but variation to 
iso-propyl in 8 caused a loss of binding. Six membered ali-
phatic rings (10-14) were better tolerated than analogues con-
taining six-membered aromatic side chains (see Supporting 
Information), likely due to their greater flexibility. However, 
expansion to a seven membered ring reduced activity.  
Table 1: Effect of aliphatic side chain substitution on bind-
ing to PB1(5) and SMARCA4 by DSF and AlphaScreen. 
 
 
Cpd Side Chain PB1(5) Tm 
(°C) a 
SMARCA4 
IC50 (M) b 
5  4.2 ± 0.6 11.0 ± 2.6 
 
6  4.3 ± 0.4 ND c 
7  4.4 ± 0.6 ND 
8  1.1 ± 0.7 ND 
9  5.8 ± 0.1 9.6 ± 1.4 
 
10  5.0 ± 0.5 6.2 ± 1.1 
 
11  4.7 ± 0.6 ND 
12  3.5 ± 0.2 7.3 ± 2.6 
 
13  4.3 ± 0.4 6.9 ± 1.5 
 
14  3.7 ± 0.4 ND 
15 
 
2.5 ± 0.6 22.0 ± 3.6 
 
a Values shown are the average of three replicates and standard 
deviation by DSF assay. b Values shown are the average of two 
replicates by AlphaScreen assay. c IC50 not determined. 
It was anticipated that compounds targeting PB1(5) might 
interact with the SMARCA2 and SMARCA4 bromodomains 
due to the similarity of their binding pockets. We confirmed 
the binding of these analogues to the SMARCA4 bromo-
domain in an AlphaScreen assay (Table 1), which established 
that the compounds had affinities for this bromodomain rang-
ing from 6.2–22.0 M.  
The improved solubility and activity of the compounds al-
lowed us to conduct isothermal calorimetry (ITC) experiments 
with analogues 9 and 10. These had KD values of 2.3 M and 
1.2 M respectively for the PB1(5) bromodomain. In both 
compounds 9 and 10, the entropy change upon binding (TS)  
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  Scheme 1: General route to core 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-ones and their derivatives.a 
 
a Reagents and conditions: (a) 4-chlorobutanoyl chloride, Et3N, THF, 0 °C to rt, 12 h, 92%; (b) tBuOK, THF, rt, 1 h, 77%; (c) N,N-
dialkylformamide, POCl3, CH2Cl2, 70 °C, 16–74%; (d) H-NR2, DMAP, EtOH, 70 °C, 24–96 h, 39–81%. For R see Table 1.  
contributed favorably to binding (TS values of 4.7 and 5.3 
kcal/mol respectively). In addition, interaction of these two 
inhibitors with PB1(5) was driven by enthalpic contributions 
(H -2.9 and -2.7 kcal/mol respectively). The underlying mo-
lecular mechanism for the observed thermodynamics was evi-
dent on analysis of the binding mode of compound 10, re-
vealed by a co-crystal with PB1(5) bromodomain (Figure 2).     
This structure demonstrated that the rigid core of 10 sits deep 
in the hydrophobic KAc binding site of PB1(5), displacing the 
four waters observed in the apo-form and most BRD-ligand 
crystal structures. The carbonyl of the 5,6-dihydropyrimidin-
4(1H)-one ring formed a direct hydrogen bond to Tyr696, 
whilst the amide hydrogen bonds to Asn739. This binding 
mode is similar to that adopted by PFI-3 and its salicylic acid 
precursor, which also displace conserved waters and form 
direct hydrogen bonds to Tyr696 and Asn739.26 These interac-
tions are in marked contrast to those in most bromodomain 
inhibitors, in which a KAc mimetic, directly hydrogen bond-
ing to the asparagine residue, forms a water-mediated hydro-
gen bond network to tyrosine using the structural conserved 
waters. The crystal structure highlighted the narrowness of the 
PB1(5) pocket, which the compound occupies well, and indi-
cated that the side chain is key in orienting the core within the 
pocket. This helped explain the lack of activity of the unsub-
stituted core. The piperidine side chain projects out from the 
pocket forming a close interaction with the hydrophobic rim of 
the binding site, explaining the loss in activity in compounds 8 
and 15, which contain more sterically demanding side chains. 
 
Figure 2: Binding modes of bromodomain inhibitors. (a) Co-
crystal structure of 10 with PB1(5) at 2.3 Å (PDB 5FH6). Hydro-
gen bonds are shown by black dashed lines. (b) Apo-crystal struc-
ture of PB1(5) (PDB: 3G0J) showing conserved crystallographic 
waters (red spheres) which are displaced in (a). 
The carbonyl of Met731 was observed to be in an unsolvated 
cavity in the structure, and it was hypothesized that substitu-
tion on the aromatic ring ortho to the carbonyl group might 
enable an additional interaction in this region. Compounds 16-
20 could be accessed by incorporating substituted 2-
aminobenzamides into the synthetic methodology previously 
developed. Compound 21 featuring hydroxyl substitution was 
obtained by deprotection of the methoxy analogues using 
BBr3. Detailed procedures are in the supporting information.  
Screening these analogues against PB1(5) by DSF showed that 
substitution of chlorine at R2 in compound 18 doubled the ob-
served Tm in comparison to unsubstituted 5, whilst bromine 
substitution gave a smaller increase (Table 2). All other substi-
tutions reduced binding compared with analogue 5. This SAR 
provides valuable compounds suitable as negative controls for 
the exploration of the biological activity of these compounds. 
Table 2: Effect of aromatic substitution on binding to the 
PB1(5) bromodomain. 
Cpd R2 PB1(5) 
Tm (°C) a 
Cpd R2 PB1(5) 
Tm (°C) a 
5 H 4.2 ± 0.6 19 Br 6.9 ± 0.9 
16 Me 1.4 ± 0.4 20 OMe -0.7 ± 0.7 
17 F 1.4 ± 0.8 21 OH 3.4 ± 0.2 
18 Cl 8.4 ± 0.6 
   
a Values shown are the average of three replicates and stand-
ard deviation.  
 
A KD of 137 nM for PB1(5) was obtained for 18 by ITC, with 
a significant increase in the enthalpic contribution to binding 
(H -6.0 kcal/mol). Since Cl/Br inclusion also increased bind-
ing of the core scaffold (Tm 2.5 °C and 3.1 °C respectively, 
see supporting information) we proposed that the improved 
interaction was due to formation of a halogen bond to the car-
bonyl of Met731. Whilst bromination would be predicted to 
give a stronger halogen bond,30 the effect is countered by ste-
ric constraints within the cavity.  
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 Table 3: Structure activity relationships of chlorinated derivatives against SWI/SNF bromodomains  
 
 
 
 
 
Tm (°C) 
Cpd Side Chain PB1(5)a  PB1(2)a PB1(3)b PB1(4)a SMAR-
CA2Aa 
SMAR-
CA2Ba 
SMAR-
CA4a 
18  8.4 2.2 1.0 0.4 4.4 2.7 3.6 
22  7.3  2.9 0.2 0.6 3.6 2.5 2.8 
23  6.9  1.2 0.2 0.4 2.6 1.3 1.4 
24  9.8  4.7 0.8 0.9 6.3 4.3 5.3 
25  7.4 1.9 0.4 0.3 2.8 1.7 2.7 
26  10.2  4.3 1.3 1.1 6.6 4.2 5.4 
27  9.2 4.0 1.4 0.9 4.8 4.1 5.6 
a Values shown are the average of three replicates. Standard deviation is < 0.6 °C. b Values are a single measurement.  
This interaction was confirmed by a co-crystal structure of 18 
with PB1(5), in which the chlorine occupies the cavity previ-
ously observed with a separation of 3.2 Å from the carbonyl 
oxygen of Met731. This is consistent with a halogen bond 
(Figure 3).30 A slight twist in the scaffold, to maximize inter-
actions with both Tyr696 and Asn739, can be observed. Com-
parison with PFI-3 shows that the interaction with Met731 has 
not been previously exploited (supporting information). 
 
Figure 3: Co-crystal structure of 18 with PB1(5) at 1.5 Å (PDB 
5FH7). (a) Cut-through illustrating positioning of chlorine in cavi-
ty. (b) Surface view illustrating fit in PB1(5) pocket.  
To improve the aqueous solubility of the chlorinated deriva-
tives, we varied the enamine substituent using the existing 
methodology to access analogues 22-27, the majority of which 
retained their affinity for the target as assessed by DSF (Table 
3). Compounds 24, 26, and 27 had greatly improved DMSO 
and aqueous solubility. The binding of these compounds to 
PB1(5) was assessed by ITC (Table 4) and all displayed simi-
lar KD values to compound 18. 
As shown in Table 3, the analogues were screened by DSF 
against other bromodomains within the SWI/SNF complex, 
including other structurally distinct bromodomains within 
protein PB1, to determine their selectivity. When interpreting 
this data, it should be noted that different proteins do not be-
have identically in DSF assays, and Tm values should not be 
viewed as an absolute scale. For example, probe PFI-3 has KD 
values by ITC of 89 nM and 48 nM for SMARCA4 and 
PB1(5) respectively, but Tm shifts of 5.1 °C and 7.5 °C.25  
Table 4: Binding of key compounds to PB1(5) was assessed 
by isothermal calorimetry. 
Cpd K ×1E6  
 (1/M) 
KD (nM) H 
(kcal/mol) 
TS 
(kcal/mol) 
18 7.29 ± 0.91 137 (157-122) -6.2  3.0 
24 7.86 ± 0.89 127 (143-114) -5.2 4.0 
26 8.09 ± 0.66 124 (135-114) -5.0 4.3 
27 7.05 ± 0.68 142 (157-129) -4.4 4.7 
28 5.88 ± 0.60 170 (189-154) -6.8 2.3 
 
 
Figure 4: Representative ITC trace, measured using 26 and the 
bromodomain of PB1(5). 30 consecutive injections of PB1(5) into 
a solution of 26 in 20 mM HEPES, 150 mM NaCl, 0.05 mM 
TCEP. Raw heats (left) and normalized injection heats with a 
nonlinear least-squares fit for a single binding site model (right) 
are shown. 
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 Table 5: Structure activity relationships of compounds bearing alkene based side chains against SWI/SNF bromodomains. 
 
 
  Tm (°C) 
Cpd Side 
Chain 
PB1(5)  PB1(2) PB1(3) PB1(4)  SMAR
CA2A 
SMAR
CA2B 
SMARC
A4A 
28  10.2  7.1 3.1 2.7 3.5 2.5 2.9 
29  6.6  2.7 0.4 0.7 2.5 1.6 2.0 
30  8.2  3.4 1.6 1.2 3.4 2.3 2.8 
31  6.0  1.4 0.7 0.8 1.4 1.0 1.1 
a Values shown are the average of three replicates. Standard deviation is <0.6 °C. b Values are a single measurement. 
 
In our screening, compounds appeared to interact with the 
bromodomains in both SMARCA2 isoforms, A and B, and in 
SMARCA4 as well as PB1(5). ITC was used to further assess 
the binding of compound 26 to SMARCA2B and SMARCA4, 
giving KD values of 262 nM and 417 nM respectively. Binding 
to the SMARCA bromodomains had not been observed prior 
to inclusion of the chlorine substitution, suggesting that the 
proposed halogen bond is again important for binding. 
The bromodomain PB1(2) also demonstrated a moderate re-
sponse, despite containing a broader KAc binding pocket than 
PB1(5). By contrast, minimal protein stabilization was ob-
served with bromodomains PB1(3) and PB1(4). This may be 
due to the tyrosine residue in the ZA loop which acts as a ‘lid’ 
to the pocket in these bromodomains.26  
We were interested to establish whether further side chain 
variation could alter selectivity within SWI/SNF bromo-
domains. Analogues 28–31 incorporating alkene side chains 
were synthesized by reaction of 6-chloro-2,3-
dihydropyrrolo[1,2-a]quinazolin-5(1H)-one (18c) with the 
appropriate aliphatic aldehydes under basic conditions (see 
supporting information for full methods). These were screened 
by DSF, which suggested reduced binding to PB1(5) for the 
majority of ligands except compound 28. When assessed by 
ITC, compound 28 had a KD of 170 nM with PB1(5). DSF 
results suggested an intriguing change in selectivity amongst 
SWI/SNF bromodomains. In contrast to all previous com-
pounds tested in this report, and the chemical probe PFI-3,26 
28 showed a stronger interaction with PB1(2) than with the 
SMARCA2/4 bromodomains. The weak binding to 
SMARCA4 was confirmed by ITC, with a KD of 2.03 μM for 
the interaction with compound 28.  
Understanding the reason for the change in affinity would help 
design of future chemical probes with selectivity for bromo-
domains not yet targeted such as PB1(2-4) and offers the intri-
guing possibility of targeting PB1 selectively over 
SMARCA2/4. We obtained a co-crystal structure of 28 with 
PB1(5) to understand its unique features. This revealed a shift 
in the ZA loop region of PB1(5), making the KAc pocket wid-
er, and increasing its similarity to the PB1(2) KAc pocket. The 
ethyl side chains interact with the hydrophobic edges of the 
pocket, and begin to occupy the ill-defined peptide-binding 
channel in PB1(5). Although no structure was obtained to con-
firm this, we propose that in SMARCA4, Ile1543 blocks this 
channel preventing the ethyl side chains being accommodated 
in the smaller pocket. 
 
Figure 5: (a) Co-crystal structure of 28 with PB1(5) at 1.6 Å (PDB 
5FH8). (b) Overlay of PDB 5FH7 (gray) of 18 and PDB 5FH8 
(cyan) of 28 showing the shift in the ZA loop of the PB1(5) do-
main on binding of 28.  
We assessed the selectivity of the most potent pan-PB1, 
SMARCA2/4 analogue 26 against representative bromo-
domains (PCAF, BRD4(1), CREBBP, TRIM33B) from other 
sub-families using DSF. No significant binding was observed. 
Finally, the ability of compound 26 to displace SMARCA2 
from chromatin was assessed using a fluorescence recovery 
after photo-bleaching (FRAP) assay (Figure 7).31 U2OS cells 
were transfected with a GFP-linked SMARCA2 construct.  In 
order to increase global histone acetylation and thereby the 
assay window the broad-spectrum histone-deacetylase 
(HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA) 
was used.  Cells transfected with a construct carrying the 
N1464F mutation, unable to bind to chromatin via the bromo-
domain were used as a positive control. Treatment of cells 
with compound 26 at 1 or 5 µM reduced FRAP recovery times 
back to that of the N1464F mutant and unstimulated levels 
indicating that compound 26 was able to displace full length 
SMARCA2 from chromatin. 
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Figure 6: Selectivity of 26. The inhibitor 26 was screened at 10 
M against selected bromodomains by DSF assay. Temperature 
shifts for screened proteins are shown on the phylogenetic tree. 
Figure 7:  Compound 26 inhibits SMARCA2 association with 
chromatin in cells.  (a) FRAP half recovery times of GFP-
SMARCA2 are significantly decreased when treated with com-
pound 26 at 1 or 5 µM as indicated. Cells expressing the 
SMARCA2 bromodomain-inactivating mutant (N1464) were 
analyzed as comparison. Significant differences to cells treated 
with SAHA of p< 0.0001 are shown by *; (b) Time dependence of 
fluorescence recovery in the bleached area of cells expressing wt 
or mutant GFP-SMARCA2 with the corresponding treatment. 
CONCLUSIONS 
We describe the optimization of an inhibitor series targeting 
bromodomains found within the SWI/SNF complex from a 
weakly potent hit with poor physicochemical properties. Im-
provement of solubility has allowed co-crystal structures to be 
obtained demonstrating the important role of water displace-
ment in the binding of these inhibitors. Chlorination of the 
series has demonstrated the potential for exploitation of previ-
ously unexplored interactions deep within the PB1(5) KAc 
binding pocket through halogen bonding. Side chain variation 
in 28 shows that the second and fifth bromodomains of PB1 
can be targeted selectively over the SMARCA2/4 helicases, in 
contrast to the selectivity shown by the chemical probe PFI-3. 
Lead inhibitor 26 displays good affinity for PB1(5), 
SMARCA4, and SMARCA2 as assessed by ITC, excellent 
selectivity within the bromodomain family and the ability to 
displace SMARCA2 from chromatin in cells, making it suita-
ble as a chemical probe with a distinct chemotype to PFI-3 and 
for further development of SWI/SNF bromodomain inhibitors. 
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